Q-omics provides the consensus-scored LCE3A profile across patient tissues and cancer cell-line models. LCE3A expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, LCE3A is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, LCE3A RNA expression shows 8,704 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight ESCA, and LUSC as cancer lineages where LCE3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCE3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCE3A survival associations across molecular data types. LCE3A RNA expression shows survival associations in the most cancer types (14), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCE3A RNA expression–survival associations across cancer types. High LCE3A expression shows unfavorable associations in KIRC, SKCM, LUAD and THYM, but favorable associations in ESCA and HNSC. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .012). Together, the overview and detailed table identify ESCA as the clearest survival context for LCE3A RNA expression.
This table summarizes LCE3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LCE3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCE3A shows lower tumor expression in BRCA, LIHC and STAD and higher tumor expression in LUSC and LUAD. The LUSC box plot shows higher LCE3A RNA expression in tumor versus normal tissue (log2 FC = +2.002, t-test p < 0.001).
This table shows molecular features associated with LCE3A in patient tissues and cancer cell lines. In patient samples, LCE3A shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, LCE3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
